Recruitment begins at two UK sites for Vamorolone Phase 2b (VISION-DMD) trial

We are pleased to announce that the VISION-DMD Phase 2b clinical trial has begun recruitment at Newcastle upon Tyne NHS Hospital Foundation Trust and Royal Hospital for Children, Glasgow.

  • 07-Feb-2019

Great Ormond Street Hospital, Leeds Teaching Hospitals and Alder Hey Children's NHS Foundation Trust will begin recruitment soon. Birmingham Heartlands Hospital is now in the early stage of set up for this trial.

Duchenne UK co-funded the successful Phase 1 study of Vamorolone with Joining Jack, the Duchenne Research Fund and MDA. Vamorolone is a drug being developed by ReveraGen Biopharma, which could provide an alternative to the current standard of care for DMD, glucocorticoid steroids. 

To date, Duchenne UK has spent more than £1.5 million through the DMD Hub to expand clinical trial capacity in the UK. This funding has allowed existing trial sites to take on more clinical trials, and has enabled other hospitals to set up a clinical trial sites for DMD.

The trial, titled: A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) is designed to evaluate the efficacy, safety pharmacodynamics and pharmacokinetics of vamorolone in comparison to corticosteroids and placebo treatments over a 24 week period. The study will also evaluate the persistence of the effect of vamorolone over a period of 48 weeks.

The study is designed to compare 2 different doses of Vamorolone to a standard dose of corticosteroids (prednisone at 0.75 mg/kg/day) and to a placebo. Across all sites, this trial will be recruiting a total of 120 ambulant DMD patients ages 4 to <7 years.

 

For more information about this trial visit the Clinical Trial Finder.

 

To receive clinical trial updates directly into your inbox, Join the Hub.